La Jolla Pharmaceutical is turning its focus to its lone FDA-approved product and another one in the pipeline after an experimental drug for a rare blood disease failed a late-stage study.
On Monday, La Jolla Pharma (NASDAQ: LJPC) said it was halting a clinical trial testing LJPC-401, its drug candidate for iron overload in patients with beta thalassemia. The company said an interim analysis showed no benefit compared to the placebo. On the same day the company said CEO George Tidmarsh had left “to pursue other interests,” and that a search for a new chief executive was underway.
The La Jolla Pharma… Read more »
UNDERWRITERS AND PARTNERS
